Further analysis showed that FN3K knockdown resensitized human NSCLC cell lines (H3255 and PC9) to erlotinib treatment29, highlighting the therapeutic potential of targeting FN3K in cancer cells that exhibit survival dependency on NRF2. The gene discussed is FN3K; the disease is cancer.